Related Experiment Videos
[MHC-class I expression on prostate carcinoma and modulation by IFN-gamma]
Michio Naoe1, Yoshiko Marumoto, Keiichiro Aoki
1Department of Pathology, Duke University Medical Center, Durham, North Carolina, USA, Department of Urology, Showa University, School of Medicine, Tokyo, Japan.
Summary
Prostate cancer exhibits reduced MHC-class I expression, correlating with fewer CD8+ T cells. Interferon-gamma (IFN-gamma) boosts MHC-class I expression, potentially enhancing tumor immunity.
Area of Science:
- Immunology
- Oncology
- Molecular Biology
Context:
- Prostate cancer is characterized by altered immune cell infiltration and antigen presentation.
- MHC-class I expression is crucial for cytotoxic T lymphocyte (CTL) recognition of tumor cells.
- Reduced tumor-infiltrating lymphocytes (TILs) are associated with poor prognosis in prostate cancer.
Purpose:
- To investigate the correlation between MHC-class I expression and CD8+ T cell infiltration in prostate cancer.
- To evaluate the effect of Interferon-gamma (IFN-gamma) on MHC-class I expression in prostate carcinoma.
Summary:
- Immunohistochemistry revealed a significant positive correlation between MHC-class I expression and CD8+ T lymphocyte infiltration in prostate cancer tissues (r = 0.705, P < 0.0001).
- Flow cytometry analysis demonstrated that IFN-gamma stimulation up-regulates MHC-class I expression on prostate carcinoma cells (p < 0.05).
Impact:
- Findings suggest that diminished MHC-class I expression may contribute to reduced TILs in prostate cancer.
- IFN-gamma, potentially secreted by CTLs, could enhance anti-tumor immunity by increasing MHC-class I expression and TILs.